Skip to main content

Table 1 Health state annual transition probabilities and utilities used in the model

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

 

Transition probabilities (95% Confidence Interval)

References

m0 BCR

➔m1 BCR

0.0288 (0.0279–0.0297)

Hernandez 2018 [17]

➔m0 CRPC

0.0279 (0.0249–0.0308)

Hirst 2012 [18]

➔m1 CRPC

Combination P(m1 BCR + m0 CRPC)

 

➔m0 BCR Death

French male mortality in 2017 (time-dependant)

Ined.fr [19]

On m0 BCR

1 - others Pm0 BCR

 

m0 CRPC

➔m1 CRPC

0.1520 (0.1080–0.1940)

Smith 2005 [20]

➔m0 CRPC Death

Combination P(0.0413 + French male mortality in 2017)

Hirst 2012, Ined.fr [18, 19]

On m0 CRPC

1 – others Pm0 CRPC

 

m1 BCR

➔m1 CRPC

0.2055 (0.1813–0.2251)

James 2015 [2]

➔m1 BCR Death

Combination P(0.1306 + French male mortality in 2017)

James 2015, Ined.fr [2, 20]

On m1 BCR

1 – others Pm1 BCR

 

m1 CRPC

➔m1 CRPC Death

Combination P(0.2933 + French male mortality in 2017)

Fizazi 2011 [21]

On m1 CRPC

1 – others Pm1 CRPC

 
 

Utilities (Standard Deviation)

References

m0 BCR

0.89 (0.14)

Torvinen 2013 [22]

m0 CRPC

0.86 (0.17)

Saad 2018 [23]

m1 BCR

0.74 (0.27)

Torvinen 2013 [22]

m1 CRPC

0.83 (0.13)

Lloyd 2015 [24]

Death

0

 
  1. BCR biochemical recurrence; CRPC castration-resistant prostate cancer; m0 patient not metastatic to bone; m1 patient metastatic to bone